DDW 2024 highlighted advances in managing recurrent C difficile infections, emphasis on the effectiveness of live biotherapeutic products and the impact of antibiotic stewardship, and more ongoing efforts in combating C difficile.
Presented at DDW 2024 by Ken Blount, the effectiveness of live biotherapeutic products in treating recurrent C difficile infections (rCDI), offers insights into microbiota alteration and prospects for management.
In a 17-year study across 2 Québec hospitals, researchers explored the relationship between antibiotic use and healthcare-associated C difficile infections.
In a small study, rCDI therapy, Rebyota, was durable in a majority of patients who were exposed to non-CDI antibiotics.
Researchers assess the efficacy of fecal microbiota transplantation (FMT) for first or second episodes of C difficile infection (CDI), demonstrating high initial cure rates and sustained in managing the condition.
A case study of an 80-year-old patient, illustrating successful management of dual H pylori and C diff infections with quadruple therapy, with key insights from Yazan Abboud, MD and Sima Vossough-Teehan, MD.
A Florida hospital takes a novel approach to healthcare-associated infection and reduces inappropriate testing by setting up guidelines.
